Anti-ANGP2/ ANGPT2/ AGPT2 monoclonal antibody

Anti-ANGP2/ ANGPT2/ AGPT2 antibody for FACS & in-vivo assay

Target products collectionGo to ANGPT2/ANGPT2 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T21960-Ab-1/ GM-Tg-hg-T21960-Ab-2Anti-Human ANGPT2 monoclonal antibodyHuman
GM-Tg-rg-T21960-Ab-1/ GM-Tg-rg-T21960-Ab-2Anti-Rat ANGPT2 monoclonal antibodyRat
GM-Tg-mg-T21960-Ab-1/ GM-Tg-mg-T21960-Ab-2Anti-Mouse ANGPT2 monoclonal antibodyMouse
GM-Tg-cynog-T21960-Ab-1/ GM-Tg-cynog-T21960-Ab-2Anti-Cynomolgus/ Rhesus macaque ANGPT2 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T21960-Ab-1/ GM-Tg-felg-T21960-Ab-2Anti-Feline ANGPT2 monoclonal antibodyFeline
GM-Tg-cang-T21960-Ab-1/ GM-Tg-cang-T21960-Ab-2Anti-Canine ANGPT2 monoclonal antibodyCanine
GM-Tg-bovg-T21960-Ab-1/ GM-Tg-bovg-T21960-Ab-2Anti-Bovine ANGPT2 monoclonal antibodyBovine
GM-Tg-equg-T21960-Ab-1/ GM-Tg-equg-T21960-Ab-2Anti-Equine ANGPT2 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T21960-Ab-1/ GM-Tg-hg-T21960-Ab-2; GM-Tg-rg-T21960-Ab-1/ GM-Tg-rg-T21960-Ab-2;
GM-Tg-mg-T21960-Ab-1/ GM-Tg-mg-T21960-Ab-2; GM-Tg-cynog-T21960-Ab-1/ GM-Tg-cynog-T21960-Ab-2;
GM-Tg-felg-T21960-Ab-1/ GM-Tg-felg-T21960-Ab-2; GM-Tg-cang-T21960-Ab-1/ GM-Tg-cang-T21960-Ab-2;
GM-Tg-bovg-T21960-Ab-1/ GM-Tg-bovg-T21960-Ab-2; GM-Tg-equg-T21960-Ab-1/ GM-Tg-equg-T21960-Ab-2
Products NameAnti-ANGPT2 monoclonal antibody
Formatmab
Target NameANGPT2
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-ANGPT2 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-373Pre-Made Nesvacumab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody
    BiosimilarGMP-Bios-ab-612Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibody
    BiosimilarGMP-Bios-ab-641Pre-Made Zansecimab biosimilar, Whole mAb, Anti-ANGPT2 Antibody: Anti-AGPT2/ANG2/LMPHM10 therapeutic antibody
    BiosimilarGMP-Bios-ab-204Pre-Made Faricimab biosimilar, Bispecific mAb, Anti-VEGFA;ANGPT2 Antibody: Anti-VPF/VEGF/MVCD1;AGPT2/ANG2/LMPHM10 therapeutic antibody
    BiosimilarGMP-Bios-INN-1034Pre-Made Trebananib Biosimilar, Fusion Protein targeting ANGPT2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AGPT2/ANG2/LMPHM10
    Target AntigenProducts DevelopingMulti-species ANGP2/ ANGPT2/ AGPT2 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorvGMAP000494Human ANGPT2 Adenovirus particle
    ORF Viral VectorpGMAP000494Human ANGPT2 Adenovirus plasmid
    ORF Viral VectorpGMLPm003845mouse Angpt2 Lentivirus plasmid
    ORF Viral VectorvGMLPm003845mouse Angpt2 Lentivirus particle


    Target information

    Target IDGM-T21960
    Target NameANGPT2
    Gene ID285,11601,89805,716811,607616,102901787,282141,100051890
    Gene Symbol and SynonymsAGPT2,Ang-2,ANG2,ANGPT2,LMPHM10
    Uniprot AccessionO15123,O35462,A0A8J8,O77802
    Uniprot Entry NameANGP2_HUMAN,ANGP2_RAT,ANGP2_CANLF,ANGP2_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index
    Diseasebreast cancer
    Gene EnsemblENSG00000091879
    Target ClassificationCheckpoint-Immuno Oncology

    The target: ANGPT2, gene name: ANGPT2, also named as AGPT2, ANG2. This gene belongs to the angiopoietin family of growth factors. The protein encoded by this gene is an antagonist of angiopoietin 1, and both angiopoietin 1 and angiopoietin 2 are ligands for the endothelial TEK receptor tyrosine kinase. Angiopoietin 2 is upregulated in multiple inflammatory diseases and is implicated in the direct control of inflammation-related signaling pathways. The encoded protein affects angiogenesis during embryogenesis and tumorigenesis, disrupts the vascular remodeling ability of angiopoietin 1, and may induce endothelial cell apoptosis. This gene serves a prognostic biomarker for acute respiratory distress syndrome. [provided by RefSeq, Aug 2020].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.